Ciezki Jay P, Klein Eric A
Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Oncology (Williston Park). 2009 Oct;23(11):960-4.
The treatment of prostate cancer presents the patient and clinician with several options. The choice of modality is often the most difficult. For low- and intermediate-risk disease, the choice is often between surgery and brachytherapy because the other major option, external-beam radiotherapy, has toxicity that generally only makes sense in the risk/benefit analysis for high-risk prostate cancer. The comparison of brachytherapy and surgery may be done on several levels. This review will focus the comparison on toxicity, the "soft" endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the "hard" endpoint of prostate cancer-specific mortality.
前列腺癌的治疗为患者和临床医生提供了多种选择。治疗方式的选择往往是最困难的。对于低风险和中风险疾病，选择通常在手术和近距离放射治疗之间，因为另一个主要选择，外照射放疗，其毒性一般仅在高风险前列腺癌的风险/效益分析中才有意义。近距离放射治疗和手术的比较可以在几个层面上进行。本综述将把比较重点放在毒性、生化无复发生存率和临床无复发生存率这些“软性”终点，以及前列腺癌特异性死亡率这个“硬性”终点上。
